Efficacy and Safety of Infliximab Biosimilar in Treatment of Moderate to Severe Psoriasis; A Single-arm Clinical Trial

NCT06591273 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

104

Enrollment

OTHER_GOV

Sponsor class

Conditions

Moderate to Severe Chronic Plaque Psoriasis

Interventions

BIOLOGICAL: Infliximab-dyyb Biosimilar (Remsima)

Sponsor

Services Institute of Medical Sciences, Pakistan